Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

ERK1/2 anticorps

MAPK1/3 Reactivité: Humain, Souris WB, FACS Hôte: Souris Monoclonal 784CT7-6-3 unconjugated
N° du produit ABIN1882239
  • Antigène Voir toutes ERK1/2 (MAPK1/3) Anticorps
    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
    Reactivité
    • 198
    • 169
    • 167
    • 23
    • 23
    • 18
    • 7
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain, Souris
    Hôte
    • 143
    • 57
    • 4
    Souris
    Clonalité
    • 140
    • 64
    Monoclonal
    Conjugué
    • 98
    • 12
    • 9
    • 9
    • 8
    • 8
    • 8
    • 8
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 4
    • 3
    • 1
    • 1
    • 1
    • 1
    Cet anticorp ERK1/2 est non-conjugé
    Application
    • 156
    • 65
    • 51
    • 51
    • 49
    • 38
    • 24
    • 23
    • 22
    • 13
    • 7
    • 4
    • 4
    • 3
    • 2
    Western Blotting (WB), Flow Cytometry (FACS)
    Purification
    This antibody is purified through a protein G column, followed by dialysis against PBS.
    Immunogène
    Purified His-tagged Erk1/2 protein was used to produced this monoclonal antibody.
    Clone
    784CT7-6-3
    Isotype
    IgG2a
    Top Product
    Discover our top product MAPK1/3 Anticorps primaire
  • Indications d'application
    WB: 1:4000. FC: 1:25
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified monoclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Date de péremption
    6 months
  • Hu, Zhou, Zhao, Wu: "Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy." dans: Scientific reports, Vol. 6, pp. 33376, (2018) (PubMed).

    Wang, Zhao, Li, Chen, Guan, Chen, Guan: "Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic NeuronsIn VivoandIn Vitroin Parkinson's Disease." dans: PPAR research, Vol. 2017, pp. 4089214, (2017) (PubMed).

    Guo, Meng, Bai, Wei, Shi, Davis, Mao: "Prostaglandin F2? induces expression of activating transcription factor 3 (ATF3) and activates MAPK signaling in the rat corpus luteum." dans: Acta histochemica, Vol. 117, Issue 2, pp. 211-8, (2015) (PubMed).

    Zhao, Ye, Wu, Liu, Yang, Gao, Chen, Zhang, Yang, Li: "Sp1-CD147 positive feedback loop promotes the invasion ability of ovarian cancer." dans: Oncology reports, Vol. 34, Issue 1, pp. 67-76, (2015) (PubMed).

    Rönnstrand: "Signal transduction via the stem cell factor receptor/c-Kit." dans: Cellular and molecular life sciences : CMLS, Vol. 61, Issue 19-20, pp. 2535-48, (2004) (PubMed).

    Sano, Liu, Lane, Piletz, Lienhard: "Insulin receptor substrate 4 associates with the protein IRAS." dans: The Journal of biological chemistry, Vol. 277, Issue 22, pp. 19439-47, (2002) (PubMed).

  • Antigène
    ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
    Autre désignation
    Erk1/2 (MAPK1/3 Produits)
    Synonymes
    anticorps erk1/2, anticorps mitogen-activated protein kinase, anticorps erk1/2
    Sujet
    Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK1/ERK2 and MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK cascade. They participate also in a signaling cascade initiated by activated KIT and KITLG/SCF. Depending on the cellular context, the MAPK/ERK cascade mediates diverse biological functions such as cell growth, adhesion, survival and differentiation through the regulation of transcription, translation, cytoskeletal rearrangements. The the MAPK/ERK cascade plays also a role in initiation and regulation of meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a number of transcription factors. About 160 substrates have already been discovered for ERKs. Many of these substrates are localized in the nucleus, and seem to participate in the regulation of transcription upon stimulation. However, other substrates are found in the cytosol as well as in other cellular organelles, and those are responsible for processes such as translation, mitosis and apoptosis. Moreover, the MAPK/ERK cascade is also involved in the regulation of the endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. The substrates include transcription factors (such as ATF2, BCL6, ELK1, ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN, GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of translation (such as EIF4EBP1) and a variety of other signaling-related molecules (like ARHGEF2, FRS2 or GRB10). Protein kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3, RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2, MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or DUSP16) are other substrates which enable the propagation the MAPK/ERK signal to additional cytosolic and nuclear targets, thereby extending the specificity of the cascade.
    Poids moléculaire
    43136
    UniProt
    P27361
Vous êtes ici:
Support technique